[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599434":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":43,"responsibleParty":78,"collaborators":81,"id":85,"slug":25,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":25,"enrollmentInfo":93,"targetDuration":25,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"University of Washington","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexamethasone","ACTIVE_COMPARATOR","Supportive care and dexamethasone 8 mg administered intravenously (using blinded packaging) once daily for up to 5 days until SBO is resolved or patient becomes surgical candidate.",[13,14],"Drug: Dexamethasone","Other: Supportive Care",{"label":16,"type":17,"description":18,"interventionNames":19},"Supportive Care","PLACEBO_COMPARATOR","Supportive care in both arms could include nasogastric tube (NGT) decompression, IV hydration, and serial abdominal exams as part of the standard of care for bowel obstruction management.",[14],[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","\\*Please see description for dexamethasone + supportive care arm.",[9],null,{"type":6,"name":16,"description":27,"armGroupLabels":28,"otherNames":25},"\\*Please see description for supportive care arm.",[9,16],[30],{"name":31,"affiliation":5,"role":32},"David Flum, MD MPH","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Kelsey Pullar, MPH","CONTACT","206.221.8247","kpullar@uw.edu",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Erin Fannon","206.685.9770","ecarney@uw.edu",[44,56,66,72],{"facility":45,"status":46,"city":47,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":25},"Columbia University Medical Center","RECRUITING","New York","10032","United States",{"type":51,"coordinates":52},"Point",[53,54],-74.00597,40.71427,{"lat":54,"lon":53},{"facility":57,"status":46,"city":58,"state":59,"zip":60,"country":49,"cosmosGeoPoint":61,"geoPoint":65,"contacts":25},"Harborview Medical Center","Seattle","Washington","98104",{"type":51,"coordinates":62},[63,64],-122.33207,47.60621,{"lat":64,"lon":63},{"facility":67,"status":46,"city":58,"state":59,"zip":68,"country":49,"cosmosGeoPoint":69,"geoPoint":71,"contacts":25},"UW Medical Center - Northwest","98133",{"type":51,"coordinates":70},[63,64],{"lat":64,"lon":63},{"facility":73,"status":46,"city":58,"state":59,"zip":74,"country":49,"cosmosGeoPoint":75,"geoPoint":77,"contacts":25},"University of Washington Medical Center Montlake","98195",{"type":51,"coordinates":76},[63,64],{"lat":64,"lon":63},{"type":32,"investigatorFullName":79,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"David Flum","Professor and Associate Chair of Research, Director of the Surgical Outcomes Research Center (SORCE), Adjunct Professor, Dept. of Pharmacy",[82],{"name":83,"class":84},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100599434",false,"NCT07084441","Comparison of Outcomes of Management of Bowel Obstruction","COMBO","Inclusion Criteria:\n\n* Adults ≥18 years of age recruited from UWMC\n* Patients presenting to surgical services through the Emergency Department, diagnosis of SBO, consulted by surgeon, and an urgent or emergency operation is deemed not necessary by surgeon.\n* Diagnosis of aSBO is established by;\n\n  1. CT findings consistent with diagnosis of SBO; and\n  2. signs and symptoms consistent with SBO; and\n  3. Adhesions from prior abdominopelvic surgery are the likely cause of SBO (absence of incarcerated hernia, internal hernia, masses, fistula, stricture, volvulus, acute episode of inflammatory bowel disease (IBD) flare, etc.).\n* Ability to provide written or electronic informed consent in English and answer teach-back questions\n\nExclusion Criteria:\n\n* Signs and symptoms of peritonitis with emergency operation planned\n* Planned urgent operation within the next 12 hours\n* Allergy to dexamethasone\n* Surgery within prior 6 weeks\n* Unable or unwilling to return or be contacted for and\u002For complete research surveys\n* Currently incarcerated in a detention facility or in police custody (patients wearing a monitoring device can be enrolled) at baseline\u002Fscreening\n* Individuals with latent infections who have an increased risk of infection.","ALL","18 Years",{"count":94,"type":95},550,"ESTIMATED","INTERVENTIONAL",[98],"PHASE4","The Comparison of Outcomes of Management of Bowel Obstruction (COMBO) trial is a patient-level randomized trial of a short course of dexamethasone + supportive care vs supportive care alone for patients with adhesion-related small bowel obstruction (aSBO). The goal of the COMBO trial is to answer the question: Can Dexamethasone increases the proportion of patients with resolution of aSBO with non-operative management (without complication) based on an established minimal important clinical difference.",[101],"Adhesive Small Bowel Obstruction",[103,104,105,106],"asbo","sbo","small bowel obstruction","dexamethasone","2026-05-05",{"date":109,"type":110},"2026-05-07","ACTUAL",{"date":112,"type":110},"2026-02-03",{"date":114,"type":95},"2030-12",{"name":5,"class":6},4]